Cellular Logistics, a pioneering biotech company, has developed CFX™, an innovative cardiac therapy aimed at promoting heart healing and preventing heart failure progression after a heart attack. This groundbreaking treatment activates repair mechanisms in damaged heart areas, stimulates new blood vessel formation, and mitigates inflammatory responses that typically lead to tissue scarring. CFX is produced using induced pluripotent stem cell technology, offering versatile application options. It can be administered as a standalone treatment to rejuvenate damaged heart tissue, or as a complementary therapy to enhance the effectiveness and retention of other treatments in the heart.
Cellular Logistics is strategically based in Madison, Wisconsin, a city renowned for its exceptional scientific environment. This setting enhances the company’s ability to innovate and advance its regenerative medicine technologies, positioning it well to make significant contributions to the field of cardiac therapy.